Tirzepatide's defining characteristic is its novel molecular structure: a single, synthetic 39-amino acid peptide meticulously designed to function as a twincretin agonist. It selectively activates receptors for two key metabolic hormones secreted by the gut in response to food intake:
Glucose-dependent Insulinotropic Polypeptide (GIP): Enhances insulin secretion, inhibits glucagon (in a glucose-dependent manner), and may influence fat metabolism and energy expenditure.
Glucagon-like Peptide-1 (GLP-1): Stimulates glucose-dependent insulin secretion, suppresses glucagon secretion, slows gastric emptying (promoting satiety), and acts centrally in the brain to reduce appetite.
Product Benefits:
The synergistic activation of both GIP and GLP-1 receptors translates into potent and multifaceted physiological effects:
1.Superior Glycemic Control: In pivotal clinical trials (SURPASS program), Tirzepatide consistently demonstrated superior reductions in HbA1c compared to placebo, basal insulin (insulin degludec), and other leading GLP-1 RAs (semaglutide 1mg and dulaglutide). A significant proportion of patients achieved HbA1c targets (<7.0% and even <6.5%) and glycemic normalization (HbA1c <5.7%).
2.Transformative Weight Loss: Tirzepatide's impact on body weight has been groundbreaking. In T2DM trials (SURPASS), it led to substantial weight reductions significantly greater than comparators. In dedicated obesity trials (SURMOUNT program) involving adults without diabetes, Tirzepatide achieved unprecedented mean weight losses (15-22% at the highest dose over 72 weeks) and enabled a large majority of participants to achieve clinically meaningful weight loss (≥5%, ≥10%, ≥15%, ≥20%).
3.Cardiometabolic Benefits: Beyond glucose and weight, Tirzepatide improves other cardiometabolic risk factors, including reductions in blood pressure and improvements in lipid profiles (lowering triglycerides, raising HDL cholesterol). While ongoing trials are specifically assessing cardiovascular outcomes (e.g., SURPASS-CVOT), its positive effects on established risk factors are highly promising.
4.Mechanisms Driving Efficacy:
- Enhanced Insulin Secretion: Potent, glucose-dependent stimulation.
- Suppressed Glucagon: Reduced in hyperglycemic states, helping lower hepatic glucose output.
- Slowed Gastric Emptying: Increases feelings of fullness (satiety).
- Reduced Appetite & Food Intake: Central nervous system effects significantly curb hunger.
Who Stands to Benefit?
Tirzepatide is currently approved for distinct, yet often overlapping, populations:
1.Type 2 Diabetes Mellitus
Adults with T2DM as an adjunct to diet and exercise to improve glycemic control.
Can be used as monotherapy or in combination with other glucose-lowering agents (e.g., metformin, SGLT2 inhibitors, basal insulin).
Particularly beneficial for patients struggling to achieve glycemic targets despite other therapies and/or those who also need significant weight loss. It represents a potent option often positioned after metformin, especially when weight loss or cardiovascular risk reduction is a priority.
2.Chronic Weight Management (Approved as Zepbound™):
Adults with obesity (BMI ≥30 kg/m²).
Adults with overweight (BMI ≥27 kg/m²) who also have at least one weight-related comorbidity (e.g., hypertension, dyslipidemia, T2DM, obstructive sleep apnea, cardiovascular disease).
Must be used in conjunction with a reduced-calorie diet and increased physical activity.
How to get Tirzepatide?
You can contact us. sales8@bpandabio.com
We Xi'an Herben Biological Technology Co., Ltd are professional supplier of peptide products in Xi'an from China.We supply high purity and good quality Retatrutide.
Tirzepatide Specification&MOQ
MOQ:1 BOX(10vials/box)
Specification: 5mg/10mg/20mg/30mg/40mg/60mg
Tirzepatide is far more than just another diabetes or weight loss drug. Its innovative dual GIP/GLP-1 receptor agonist mechanism represents a significant scientific advancement, translating into unparalleled efficacy for glycemic control and weight reduction. Approved for adults with T2DM and for chronic weight management (obesity or overweight with comorbidities), it offers a powerful tool to address two intertwined global epidemics. With a robust pipeline exploring its potential in heart failure, sleep apnea, NASH, and beyond, Tirzepatide is poised to become a cornerstone therapy for a wide spectrum of cardiometabolic diseases. While challenges regarding access and long-term data remain, its current impact and future potential solidify its status as a transformative agent in modern medicine, offering new hope for millions struggling with the complex burdens of diabetes and obesity.
